Vaidya Sane Ayurved Laboratories Ltd

Vaidya Sane Ayurved Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Vaidya Sane Ayurved Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Vaidya Sane Ayurved Laboratories Ltd is rated Sell by MarketsMOJO. This rating was last updated on 18 May 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 29 May 2026, providing investors with the latest perspective on the company’s position.

Vaidya Sane Ayurved Laboratories Ltd has witnessed a significant shift in its valuation parameters, moving from a non-qualifying valuation status to being categorised as very expensive. This change comes amid a sharp 20% drop in its share price, reflecting heightened market volatility and investor caution in the hospital sector micro-cap space.

At Rs 201.05, sellers were still queuing — but there were no buyers willing to take the other side. Vaidya Sane Ayurved Laboratories Ltd locked at its lower circuit of 20.0% on 18 May 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

Vaidya Sane Ayurved Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 07 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Vaidya Sane Ayurved Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

At Rs 248.25, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vaidya Sane Ayurved Laboratories Ltd locked at its upper circuit of 19.99% on 27 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Vaidya Sane Ayurved Laboratories Ltd is rated Sell by MarketsMOJO. This rating was last updated on 10 March 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 26 April 2026, providing investors with the latest perspective on the company’s position.

Vaidya Sane Ayurved Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 March 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with the latest comprehensive analysis.

Vaidya Sane Ayurved Laboratories Ltd is rated Sell by MarketsMOJO. This rating was last updated on 10 March 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 04 April 2026, providing investors with the latest perspective on the company’s position.

Vaidya Sane Ayurved Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Vaidya Sane Ayurved Laboratories Ltd is rated Sell by MarketsMOJO. This rating was last updated on 10 March 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 12 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Vaidya Sane Ayurved Laboratories Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting a deterioration in the stock’s medium to long-term momentum and raising concerns about sustained weakness in the hospital sector micro-cap.

Vaidya Sane Ayurved Laboratories Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 03 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Vaidya Sane Ayurved Laboratories Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 03 June 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Vaidya Sane Ayurved Laboratories Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 03 June 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 February 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trend, and technical outlook.

Vaidya Sane Ayurved Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.